Your browser doesn't support javascript.
loading
Roles of Cholecystokinin in the Nutritional Continuum. Physiology and Potential Therapeutics.
Miller, Laurence J; Harikumar, Kaleeckal G; Wootten, Denise; Sexton, Patrick M.
Afiliación
  • Miller LJ; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, AZ, United States.
  • Harikumar KG; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, AZ, United States.
  • Wootten D; Drug Discovery Biology theme, Monash Institute for Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
  • Sexton PM; Drug Discovery Biology theme, Monash Institute for Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Front Endocrinol (Lausanne) ; 12: 684656, 2021.
Article en En | MEDLINE | ID: mdl-34149622
Cholecystokinin is a gastrointestinal peptide hormone with important roles in metabolic physiology and the maintenance of normal nutritional status, as well as potential roles in the prevention and management of obesity, currently one of the dominant causes of direct or indirect morbidity and mortality. In this review, we discuss the roles of this hormone and its receptors in maintaining nutritional homeostasis, with a particular focus on appetite control. Targeting this action led to the development of full agonists of the type 1 cholecystokinin receptor that have so far failed in clinical trials for obesity. The possible reasons for clinical failure are discussed, along with alternative pharmacologic strategies to target this receptor for prevention and management of obesity, including development of biased agonists and allosteric modulators. Cellular cholesterol is a natural modulator of the type 1 cholecystokinin receptor, with elevated levels disrupting normal stimulus-activity coupling. The molecular basis for this is discussed, along with strategies to overcome this challenge with a corrective positive allosteric modulator. There remains substantial scope for development of drugs to target the type 1 cholecystokinin receptor with these new pharmacologic strategies and such drugs may provide new approaches for treatment of obesity.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Trofoterapia Asunto principal: Colecistoquinina / Receptores de Colecistoquinina / Obesidad Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Trofoterapia Asunto principal: Colecistoquinina / Receptores de Colecistoquinina / Obesidad Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos